Compare AMH & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMH | KRYS |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | 1598 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.3B |
| IPO Year | N/A | 2017 |
| Metric | AMH | KRYS |
|---|---|---|
| Price | $33.31 | $338.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 11 |
| Target Price | $34.92 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 2.1M | 333.5K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $389,130,000.00 |
| Revenue This Year | $2.69 | $38.74 |
| Revenue Next Year | $2.26 | $32.53 |
| P/E Ratio | ★ $26.59 | $185.37 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $27.22 | $130.50 |
| 52 Week High | $36.83 | $382.54 |
| Indicator | AMH | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 46.70 |
| Support Level | $31.34 | $246.17 |
| Resistance Level | $33.57 | $382.33 |
| Average True Range (ATR) | 0.58 | 17.08 |
| MACD | -0.05 | -5.47 |
| Stochastic Oscillator | 25.50 | 26.78 |
American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.